Foghorn Therapeutics Inc (FHTX)
5.35
+0.11
(+2.10%)
USD |
NASDAQ |
Jun 21, 16:00
5.345
0.00 (0.00%)
After-Hours: 20:00
Foghorn Therapeutics Enterprise Value: 21.17M for June 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 21, 2024 | 21.17M |
| June 20, 2024 | 16.49M |
| June 18, 2024 | 16.06M |
| June 17, 2024 | 38.21M |
| June 14, 2024 | 16.91M |
| June 13, 2024 | 32.24M |
| June 12, 2024 | 50.13M |
| June 11, 2024 | 47.15M |
| June 10, 2024 | 41.19M |
| June 07, 2024 | 49.28M |
| June 06, 2024 | 58.65M |
| June 05, 2024 | 57.37M |
| June 04, 2024 | 35.23M |
| June 03, 2024 | 57.37M |
| May 31, 2024 | 41.61M |
| May 30, 2024 | 40.34M |
| May 29, 2024 | 33.10M |
| May 28, 2024 | 40.34M |
| May 24, 2024 | 33.52M |
| May 23, 2024 | 49.28M |
| May 22, 2024 | 58.22M |
| May 21, 2024 | 58.22M |
| May 20, 2024 | 48.85M |
| May 17, 2024 | 27.99M |
| May 16, 2024 | 40.76M |
| Date | Value |
|---|---|
| May 15, 2024 | 18.62M |
| May 14, 2024 | 34.80M |
| May 13, 2024 | 34.80M |
| May 10, 2024 | 30.11M |
| May 09, 2024 | 46.30M |
| May 08, 2024 | 48.00M |
| May 07, 2024 | 33.10M |
| May 06, 2024 | 41.61M |
| May 03, 2024 | 48.43M |
| May 02, 2024 | 53.54M |
| May 01, 2024 | 42.89M |
| April 30, 2024 | 25.86M |
| April 29, 2024 | 37.35M |
| April 26, 2024 | 27.13M |
| April 25, 2024 | 16.06M |
| April 24, 2024 | 15.21M |
| April 23, 2024 | 13.08M |
| April 22, 2024 | 8.396M |
| April 19, 2024 | 19.04M |
| April 18, 2024 | 28.84M |
| April 17, 2024 | 39.48M |
| April 16, 2024 | 50.13M |
| April 15, 2024 | 65.46M |
| April 12, 2024 | 109.32M |
| April 11, 2024 | 134.02M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-150.99M
Minimum
Mar 22 2023
891.66M
Maximum
Dec 18 2020
165.52M
Average
86.37M
Median
Enterprise Value Benchmarks
| Viridian Therapeutics Inc | 408.46M |
| CEL-SCI Corp | 64.56M |
| AIM ImmunoTech Inc | 13.37M |
| IGC Pharma Inc | 33.81M |
| NovaBay Pharmaceuticals Inc | 2.982M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.02M |
| Revenue (Quarterly) | 5.05M |
| Total Expenses (Quarterly) | 33.24M |
| EPS Diluted (Quarterly) | -0.59 |
| Profit Margin (Quarterly) | -495.4% |
| Earnings Yield | -41.12% |
| Normalized Earnings Yield | -41.12 |